Protagonist Therapeutics, Inc. (PTGX)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Protagonist Therapeutics, Inc. keeps $80 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Based on preliminary results for Protagonist Therapeutics’ third fiscal quarter of 2026, reported November 5, 2026, the company posted a net loss, with EPS of -$0.32 and net income of roughly -$12.8 million, as it continued investing across its peptide-based pipeline spanning hematological and other blood disorders as well as inflammatory and immune-mediated diseases, including programs such as rusfertide (PTG-300), PN-943, and PN-235. With beat/miss comparisons not available for this release, results are best read through the bottom-line print and loss level rather than against consensus benchmarks for the reported period. Looking ahead, next-period consensus calls for EPS of -$0.32 on revenue of $35.3 million.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on discovering and advancing peptide-based therapies for blood, inflammatory, and immune-mediated disorders. The company develops clinical candidates across hematological and broader blood conditions as well as inflammatory disease, and generated $46.0 million of revenue in FY2025.
Today's Snapshot
PTGX closed 2.1% lower at 121.40, while its sector was flat.
Trading Volume
Above 10d avg 542.1K
593K
vs S&P 500 Today
Outperforming Market
+1.38%
Updated: November 20, 2026 at 21:09 UTC
PTGX Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$119.34 - $136.26Sell
- RSI (14)31.51Neutral
- Stochastic %K (14, 3, 3)12.19Buy
- MACD Level (12, 26)-4.26Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.